A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)

Lori J. Goldstein, Fengmin Zhao, Molin Wang, Ramona F. Swaby, Joseph A. Sparano, Neal J. Meropol, Kapil N. Bhalla, Christine M. Pellegrino, R. Katherine Alpaugh, Carla I. Falkson, Paula Klein, George W. Sledge

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)'. Together they form a unique fingerprint.

Medicine & Life Sciences